ACT 2 Logo
TREATMENT · 4-IN-1 HAIR LOSS · PRODUCT

Topical vs Oral Finasteride and Minoxidil

Pattern hair loss has two drugs with real evidence, and each now comes in two routes. Finasteride was a pill for twenty-five years and is now also a scalp solution. Minoxidil was a scalp foam for thirty years and is now, increasingly, a pill. The routes are not interchangeable — they differ in how much drug reaches the rest of the body, in what the trials show, and in who they suit — and the choice between them is the decision this page is about.

The main page covers what our topical combination does and who it is for. The finasteride side-effects page covers the safety question that drives most of the interest in "topical."

See if you're eligibleA short, confidential online assessment. Reviewed by a clinician.

Finasteride: pill or solution

Oral finasteride is the reference treatment for male pattern hair loss. It blocks the enzyme that converts testosterone to DHT — the hormone that shrinks follicles on a susceptible scalp — throughout the body, cutting blood DHT by well over half and scalp DHT by a similar amount. Its trials run to five years, its effect on maintaining and modestly regrowing hair is well established, and its side-effect profile, including the sexual side effects and the post-finasteride controversy, is on the side-effects page.

Topical finasteride applies the same molecule to the scalp. The logic is that DHT needs to be reduced in the follicle, not in the whole body, and that a scalp solution can achieve the first with less of the second. The trials bear this out, up to a point. A phase 3 trial published in 2022, comparing a topical finasteride solution with the oral tablet and with placebo over six months, found the topical product maintained and increased hair count to a degree comparable with the tablet — while lowering blood DHT by roughly a third rather than roughly a half or more. Later studies and a 2024–25 meta-analysis have been consistent: similar scalp effect, lower but not negligible systemic exposure.

So topical finasteride is not "finasteride without the systemic effect." It is finasteride with less of it — a meaningful difference for the man whose concern is systemic side effects, and one the FDA's 2025 alert on compounded topical finasteride shows is not a guarantee.

Minoxidil: solution or pill

Topical minoxidil — the foam or liquid — is the other established treatment, with decades of trials and approval for both men and women. Its limitations are practical: twice-daily application to a scalp that then feels sticky or greasy, irritation from the propylene glycol in the liquid, and a large share of users who stop within a year because the routine defeats them. Its effect is real but modest, and it depends on the scalp's ability to convert minoxidil to its active form, which varies between people.

Oral minoxidil began as a blood-pressure drug, and hair growth was its side effect. In the last several years dermatologists have repurposed it for hair loss at a small fraction of the antihypertensive strength, and it has become one of the most-prescribed hair treatments in the specialty on the strength of large observational series showing better adherence, an effect at least as good as the topical, and hair growth on the whole body rather than the scalp alone — which is the main complaint.

Oral minoxidil is a systemic vasodilator, and it comes with a set of cardiovascular considerations that the topical does not. Those are the subject of the oral minoxidil and the heart page, and they are the reason it is not simply "the better minoxidil."

Why a 4-in-1 topical exists

Our treatment is a topical combination: finasteride and minoxidil applied together to the scalp, with two further agents that address scalp inflammation and improve penetration. The reasoning is the one above, applied twice. The finasteride is topical because the goal is DHT reduction in the follicle with the least systemic exposure the route allows. The minoxidil is topical because it avoids the vasodilator effects of the pill. And they are combined because the two drugs work by different mechanisms — one hormonal, one vascular — and trials of the combination show more effect than either alone.

That is a defensible design, and it is honest to say what it is not: it is not the maximum-strength option. A man who wants the largest possible effect regardless of systemic exposure would take oral finasteride and oral minoxidil, with the monitoring each requires. A man who wants effect with the least systemic exposure the evidence supports takes the topical combination. Most men, in our experience, are the second, and the main page sets out what they can expect.

Choosing

Topical finasteride over oral: when sexual or mood side effects are the concern, when a partner is or may become pregnant (with the transfer caution observed strictly), or when a man has stopped the tablet before because of side effects and wants to try again with less exposure.

Oral finasteride over topical: when a man has been on it for years without trouble and sees no reason to change, or when the topical routine is not going to happen.

Topical minoxidil over oral: when there is any cardiovascular history, when body-hair growth would be unacceptable, or when the heart page's screening raises anything.

Oral minoxidil over topical: when the topical routine has failed on adherence, when the scalp cannot tolerate the solution, and when the cardiovascular screen is clear — with a clinician who monitors it.

We prescribe the topical combination; oral finasteride and oral minoxidil are decisions for a clinician who will monitor them, and we will say so if they are the better fit.

Questions

Frequently asked questions

  • In the phase 3 trial, comparably effective on scalp hair count over six months, while lowering blood DHT by about a third rather than a half or more. Similar effect, less systemic exposure — not none.

  • Fewer on average, but it is absorbed, and the FDA issued an alert on compounded topical finasteride products in 2025 after reports of persistent side effects. "Topical" reduces the risk; it does not remove it.

  • It has better adherence and at least comparable effect in large observational series, plus body-hair growth and cardiovascular considerations the topical does not have. It is a systemic drug and needs screening and monitoring.

  • They work by different mechanisms — hormonal and vascular — and the combination outperforms either alone in trials.

  • Topical finasteride and minoxidil plus two agents for scalp inflammation and penetration. The full list is on the main page and the label.

  • Only with strict care to avoid transfer — the product must not contact a pregnant woman's skin. The FDA alert flagged this specifically. Discuss it at assessment.

Your next step

Where this fits in your plan

The 4-in-1 Hair Loss Treatment page covers our topical combination; this page is why it is topical. The side-effects page and the heart page are the two safety reads before starting anything.

We measure first. Then we act.

References

  1. Piraccini BM et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology 2022;36:286–294.
  2. Vañó-Galván S et al. Safety of oral minoxidil for the treatment of hair loss: a multicenter study of 1404 patients. Journal of the American Academy of Dermatology 2021;84:1644–1651.
  3. Kaufman KD et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology 1998;39:578–589.
  4. Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology 2002;47:377–385.
  5. FDA. Alert on compounded topical finasteride products, April 22 2025.
  6. Gupta AK et al. Topical finasteride for male and female pattern hair loss: a systematic review.

How we write and review our content

ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.

Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.

Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.

We measure first. Then we act.

Start with a baseline. Then decide about 4-in-1 hair loss treatment.